



ONYCHOMYCOSIS – 1 IN 4 INFECTED

PAINFUL NAIL FUNGAL CONDITION WITH NO CURE

ArrayPatch Ltd, an award-winning Irish biotech, is leveraging its proprietary DerMap™ dissolving microneedle patch technology to develop more effective and safer treatments targeting billion-dollar global markets

INVESTMENT OPPORTUNITY



Invest in the company's €3M seed round (EIIS qualifying) as it advances a promising new therapeutic **ITZ-DerMap™** for **ONYCHOMYCOSIS**.



ITZ-DerMap™ is a patented microneedle patch formulation of generic anti-fungal medicine itraconazole - preparing for clinical trials.

\$6_{BN}

ONYCHOMYCOSIS is a \$6BN global market with significant unmet medical need. A successful treatment can generate over €150M revenue per annum.

'..This is a very exciting technology and has excellent potential..'

LEADING UK GP

'..ITZ-DerMap™ will have a significant market..'

U.S. DERMATOLOGIST

ArrayPatch Background


- Founded in 2024, led by a team with over 75 years' development and commercialisation expertise
- Technology spun out of University College Cork (UCC) with over €1.3M invested
- Lead product in development, ITZ-DerMap™, is for onychomycosis (nail fungal infection), a \$6BN market
- Key opinion leaders and contract manufacturing/research organisations in place to support development
- Technology potential recognised - Pharma Industry Awards; SSPC; IDEATE Ireland

DerMap™ Dissolving Microneedle Patch Technology

The DerMap™ technology was developed to overcome several key limitations of other microneedle delivery approaches while bringing the benefits of this delivery approach to select diseases for the first time. Uniquely, the microneedles in the DerMap™ technology are made entirely of the drug being delivered hence there is no need for 'polymers' as used in other approaches. This allows for a greater quantity of drug to be delivered thus providing greater efficacy while avoiding any safety concerns over polymer use. On application of the patch, the microneedles penetrate the skin and dissolve, thus imparting a targeted treatment to the site.

Lead Product – ITZ-DerMap™

- First of its kind microneedle patch delivery of an anti-fungal medicine to treat onychomycosis
- Application targets delivery of medicine beneath the skin and directly to the root cause of the infection
- Avoids serious liver damaging side effects associated with current oral systemic therapies
- Addresses poor efficacy of topical approaches which don't target the nail root
- Pre-clinical proof of concept supports claims for significantly greater efficacy and safety
- Lower risk and shorter development timeline as delivering an already approved medicine (itraconazole)
- Global annual revenue potential in excess of €300M



Pipeline – aimed at markets worth \$60BN

The pipeline includes several exciting follow-on product opportunities leveraging the DerMap™ microneedle patch technology. Comprising treatments for skin cancer, psoriasis and hormone replacement therapy - global markets worth in excess of \$60BN. Potential partnering represents an opportunity to generate additional revenue.

Seeking €3M seed funding to complete ITZ-DerMap™ clinical proof of concept in 2026

The company is now seeking €3M seed investment to scale up manufacturing of lead ITZ-DerMap™ and conduct a value enhancing Phase 1/2 clinical trial in 14 onychomycosis patients. The results from this initial trial will pave the way for a final Phase 3 trial in 2027/8, but may also provide an early exit opportunity for investors in 2026. Commitments of over €1.8M already secured, EIS status allows for up to 50% investor tax relief.

Following seed investment, a further €10-12M will be raised (via fundraising or partnering revenue) in 2026 to fund a Phase 3 study to support final regulatory approval and launch in the market. Precedent transactions in this sector support a return on investment of between 10-20x for seed investors in a time period within 3 to 4 years.



Contact:
Dr Waleed Faisal, CEO
Tel: +353 85 7223337
Email: waleed.faisal@array-patch.com

Array
Patch